68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era

Q: What does this research mean for the field?

68Ga-FAPI demonstrates superior lesion detection and diagnostic accuracy compared to 18F-FDG PET/CT for recurrent ovarian cancer, particularly in the PARPi era. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

Zheng Feng; Shuai Liu; Yangjun Wu; Xingzhu Ju; Xiaojun Chen; Rui Bi; Ke Zuo; Shaoli Song; X. Wu; H. H. Wen

doi:10.1097/cm9.0000000000003976

March 11, 2026Chinese Medical JournalOpen Access

68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research evaluates the effectiveness of 68Ga-FAPI compared to 18F-FDG PET/CT in recurrent ovarian cancer diagnosis during the PARP inhibitor treatment period.
Compared 68Ga-FAPI and 18F-FDG PET/CT in recurrent ovarian cancer patients.
Assessed lesion detection rates and diagnostic accuracy.
Investigated underlying mechanisms of resistance in FAPI+/FDG- lesions.
68Ga-FAPI showed superior lesion detection compared to 18F-FDG.
Enhanced diagnostic accuracy was observed in patients undergoing PARP inhibitor treatment.
Resistance mechanisms such as hypoglycolysis and CAF activation contribute to differing PET responses.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Findings demonstrate enhanced lesion detection in recurrent ovarian cancer, highlighting the advantages of FAP inhibitors.

Abstract

68Ga-FAPI demonstrated superior lesion detection and diagnostic accuracy compared with 18F-FDG PET/CT for recurrent ovarian cancer, especially in the PARPi era. Hypoglycolysis and CAF activation may underlie PARPi resistance in FAPI+/FDG- lesions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Feng et al. (2026) studied this question.

synapsesocial.com/papers/69b4fc33b39f7826a300ce99 https://doi.org/10.1097/cm9.0000000000003976

View Full Paper

Ask AI

Bookmark

Share

68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading